Tag:
epilepsy
Latest Headlines
Latest Headlines
Supernus plots product launches as it dusts off $76M IPO attempt
Supernus Pharmaceuticals has finally dusted off the paperwork and suggested a $12 to $14 price range on some 5.8 million shares.
Mylan concocts ready-to-use epilepsy drug variation
Global generic drug manufacturer Mylan ( $MYL ) has begun selling a version of the anti-epilepsy drug Levetiracetam for intravenous use in a variation intended to be safer and easy to use. Doses are
Biomarker may signal cognitive decline
Losing cognitive abilities is one of the most distressing symptoms of neurodegenerative disorders such as multiple sclerosis. Researchers from the NYU Langone Medical Center, publishing in the
FDA refuses to file Eisai app for new epilepsy drug
The FDA has taken a red pen to Eisai's application for approval of perampanel for epilepsy patients, handing the Japan-based drugmaker a refusal to file letter for the NDA submitted in May. It's
FDA provides conditional OK for GSK/Valeant's epilepsy drug
GlaxoSmithKline's ( $GSK ) $820 million gamble on Valeant's ( $VRX ) epilepsy drug Potiga (ezogabine in the U.S. and retigabine elsewhere) has paid off with an FDA approval that could pave the way to
Does Eisai's epilepsy drug work? Yes and no
Some seemingly contradictory headlines are coming out of the American Academy of Neurology meeting in Honolulu, where Bloomberg reports that Eisai's epilepsy drug perampanel did not significantly
FDA rejects a new epilepsy drug from Valeant, GSK
The FDA has rejected a new epilepsy drug from Valeant Pharmaceuticals ($VRX) and GlaxoSmithKline ($GSK), saying that the drug companies have to meet some "non-clinical" demands from regulators for
FDA panel backs new epilepsy drug from GSK, Valeant
GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts, putting them on track to a likely approval. The experts unanimously
FDA staffers weighs risks, rewards of new epilepsy drug
Staffers at the FDA have red-flagged their concern about cases of urinary retention tracked in some patients taking Valeant Pharmaceutical's experimental new epilepsy medicine Potiga (ezogabine),
